1Y Target$230.78Near-term target
5Y Target$323.20Compound horizon
10Y Target$475.08Long-dated conviction
FCF$4.4bTTM · 03/26BFCF $4.4b — solid, comfortably covers operations and capital return · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+12.9%TTM YoYB+Revenue +12.9% — above sector median, healthy trajectory · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E3.48DD/E 3.48 — very high leverage
P/E30.2xC+P/E 30.2 — elevated; requires sustained growth to justify
PEG2.35proxyCPEG 2.35 — expensive relative to growth rate · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $47.0b. 14% off the 52-week high of $233.60. Revenue growing +13%, comfortably above the S&P median.
Moat
ROE 37% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
D/E 3.48 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Net margin 0.6% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $230.78 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $323.20 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $475.08 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.